Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 7, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,413 pence per share; lowest price paid was 1,397 pence per share.
- Treasury Holdings (Settled): 509,797,927 shares (9.17% of total issued share capital).
- Treasury Holdings (Including Unsettled): 511,697,927 shares (10.14% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,047,316,374 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 500,000 shares for Treasury. Consequently, the total voting rights held in Treasury increased to 10.14% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the company's latest annual report to confirm the 9.17% and 10.14% figures.
- Confirm the settlement status of the 500,000 shares purchased on March 7, 2012.
- Review the Financial Services Authority's Disclosure and Transparency Rules to understand notification thresholds based on the 5,047,316,374 shares in issue.